Invivyd Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Great. Good afternoon, everyone. Thanks for joining us for this fireside chat with Invivyd. I'm Evan Wang, one of our biopharma team's senior analysts, and I'm joined by Invivyd's CEO, Dave Hering.
Good to be here.
Questions & Answers
Yeah. Great to have you. Dave, just to set the stage for those unfamiliar, can you just give a brief introduction on Invivyd and help frame the unmet need with COVID?
Yeah, course. So we're a biopharmaceutical company focused on monoclonal antibody therapies, really targeting people with immune-compromised populations, vulnerable populations, people who aren't going to get all the protection they need from a vaccine or other therapy. Targeting this in a serial platform way to be able to continuously provide these products and really focused
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |